Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.08 USD | +0.07% | +0.22% | -17.20% |
12:07pm | North American Morning Briefing : More Tech -2- | DJ |
Apr. 24 | HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69 | MT |
Evolution of the average Target Price on Gilead Sciences, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Gilead Sciences, Inc.
HSBC | |
Argus | |
Cantor Fitzgerald | |
BMO Capital | |
Leerink Partners | |
UBS | |
Goldman Sachs | |
Morgan Stanley | |
Wells Fargo Securities | |
Mizuho Securities | |
Truist Securities | |
RBC Capital Markets | |
Oppenheimer | |
Piper Sandler | |
TD Cowen | |
Barclays | |
Deutsche Bank Securities | |
BofA Securities | |
SVB Securities LLC | |
Cowen | |
Maxim | |
JPMorgan Chase | |
SVB Leerink | |
Credit Suisse | |
Bernstein | |
Redburn | |
DZ BANK | Elmar Kraus |
EPS Revisions
- Stock Market
- Equities
- GILD Stock
- Consensus Gilead Sciences, Inc.